Meeting
2017 ASCO Annual Meeting
Predictors of prolonged benefit from palbociclib (PAL) plus fulvestrant (F) in women with endocrine-resistant hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2–) advanced breast cancer (ABC) in PALOMA-3.
Authors
Massimo Cristofanilli
Robert H. Lurie Cancer Center of Northwestern University, Feinberg School of Medicine, Chicago, IL
Massimo Cristofanilli , Angela DeMichele , Carla Giorgetti , Dennis J. Slamon , Seock-Ah Im , Norikazu Masuda , Shailendra Verma , Sherene Loi , Marco Colleoni , Kathy Puyana Theall , Xin Huang , Cynthia Huang Bartlett , Nicholas C. Turner
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Clinical Trial Registration Number
NCT01942135
Citation
J Clin Oncol 35, 2017 (suppl; abstr 1050)
DOI
10.1200/JCO.2017.35.15_suppl.1050
Abstract #
1050
Poster Bd #
42
Abstract Disclosures
Similar Posters
First Author: Gabrielle Betty Rocque
Poster
2018 ASCO Annual Meeting
Hematologic adverse events following palbociclib (PAL) dose reduction in patients (pts) with hormone receptor‒positive (HR+)/human epidermal growth factor receptor 2‒negative (HER2‒) advanced breast cancer (ABC): Pooled analysis from randomized phase 2 and 3 studies.
First Author: Sunil Verma
Poster
2018 ASCO Annual Meeting
Treatment effect of palbociclib (PAL) plus endocrine therapy (ET) by prognostic and intrinsic subtype: A joint analysis of PALOMA2 and PALOMA3.
First Author: Richard S. Finn
Poster
2017 ASCO Annual Meeting
Palbociclib exposure-response analyses in second-line treatment of hormone-receptor positive advanced breast cancer (ABC).
First Author: Wan Sun